Docality.com Logo
 
Dr. Jorge  Antunez De Mayolo  Md image

Dr. Jorge Antunez De Mayolo Md

3659 S Miami Ave Ste. 2001
Miami FL 33133
305 548-8801
Medical School: Other - 1983
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: Yes
Participates In EHR: Yes
License #: ME0047826
NPI: 1407844798
Taxonomy Codes:
207RH0003X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Jorge Antunez De Mayolo is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:38220 Description:Bone marrow aspiration Average Price:$644.00 Average Price Allowed
By Medicare:
$89.64
HCPCS Code:96413 Description:Chemo iv infusion 1 hr Average Price:$686.00 Average Price Allowed
By Medicare:
$148.50
HCPCS Code:38221 Description:Bone marrow biopsy Average Price:$688.00 Average Price Allowed
By Medicare:
$176.99
HCPCS Code:J3488 Description:Reclast injection Average Price:$580.00 Average Price Allowed
By Medicare:
$223.92
HCPCS Code:96417 Description:Chemo iv infus each addl seq Average Price:$334.00 Average Price Allowed
By Medicare:
$76.39
HCPCS Code:96365 Description:Ther/proph/diag iv inf init Average Price:$304.00 Average Price Allowed
By Medicare:
$77.83
HCPCS Code:99205 Description:Office/outpatient visit new Average Price:$432.00 Average Price Allowed
By Medicare:
$220.59
HCPCS Code:99223 Description:Initial hospital care Average Price:$412.00 Average Price Allowed
By Medicare:
$216.21
HCPCS Code:99215 Description:Office/outpatient visit est Average Price:$301.15 Average Price Allowed
By Medicare:
$151.96
HCPCS Code:96415 Description:Chemo iv infusion addl hr Average Price:$156.00 Average Price Allowed
By Medicare:
$32.54
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$232.00 Average Price Allowed
By Medicare:
$108.99
HCPCS Code:96367 Description:Tx/proph/dg addl seq iv inf Average Price:$152.00 Average Price Allowed
By Medicare:
$34.33
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$224.00 Average Price Allowed
By Medicare:
$113.02
HCPCS Code:J2469 Description:Palonosetron hcl Average Price:$100.00 Average Price Allowed
By Medicare:
$18.74
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$148.00 Average Price Allowed
By Medicare:
$76.68
HCPCS Code:96372 Description:Ther/proph/diag inj sc/im Average Price:$93.00 Average Price Allowed
By Medicare:
$25.76
HCPCS Code:96361 Description:Hydrate iv infusion add-on Average Price:$73.00 Average Price Allowed
By Medicare:
$16.58
HCPCS Code:85025 Description:Complete cbc w/auto diff wbc Average Price:$35.00 Average Price Allowed
By Medicare:
$11.02
HCPCS Code:J7050 Description:Normal saline solution infus Average Price:$19.00 Average Price Allowed
By Medicare:
$0.28
HCPCS Code:36415 Description:Routine venipuncture Average Price:$19.00 Average Price Allowed
By Medicare:
$3.00
HCPCS Code:J0881 Description:Darbepoetin alfa, non-esrd Average Price:$15.00 Average Price Allowed
By Medicare:
$3.28
HCPCS Code:J1720 Description:Hydrocortisone sodium succ i Average Price:$10.00 Average Price Allowed
By Medicare:
$4.20
HCPCS Code:J1200 Description:Diphenhydramine hcl injectio Average Price:$3.00 Average Price Allowed
By Medicare:
$0.77
HCPCS Code:J1100 Description:Dexamethasone sodium phos Average Price:$1.00 Average Price Allowed
By Medicare:
$0.12

HCPCS Code Definitions

38220
Bone marrow; aspiration only
96415
Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
38221
Bone marrow; biopsy, needle or trocar
96361
Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)
96372
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
96365
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96367
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)
96413
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99215
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.
96417
Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)
99205
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family.
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
J1200
Injection, diphenhydramine hcl, up to 50 mg
J1100
Injection, dexamethasone sodium phosphate, 1mg
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
J2469
Injection, palonosetron hcl, 25 mcg
J1720
Injection, hydrocortisone sodium succinate, up to 100 mg
J3488
Injection, zoledronic acid (reclast), 1 mg
J7050
Infusion, normal saline solution , 250 cc
J0881
Injection, darbepoetin alfa, 1 microgram (non-esrd use)

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1790773760
Radiation Oncology
4,999
1538125836
Diagnostic Radiology
3,571
1316903768
Hematology/Oncology
3,258
1750377438
Pulmonary Disease
2,920
1780632109
Nephrology
2,682
1619955671
Diagnostic Radiology
2,419
1588650204
Pulmonary Disease
2,038
1316977473
Cardiovascular Disease (Cardiology)
1,916
1104812916
Pulmonary Disease
1,764
1093790313
Emergency Medicine
1,689
*These referrals represent the top 10 that Dr. Antunez De Mayolo has made to other doctors

Publications

Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Overexpression of COX-2 correlates with advanced stage and worse outcomes in non-small-cell lung cancer (NSCLC), possibly as a result of elevated levels of COX-2-dependent prostaglandin E2 (PGE2). Exploratory analyses of studies that used COX-2 inhibitors have demonstrated potentially superior outcome in patients in whom the urinary metabolite of PGE2 (PGE-M) is suppressed. We hypothesized that patients with disease defined by PGE-M suppression would benefit from the addition of apricoxib to second-line docetaxel or pemetrexed.Patients with NSCLC who had disease progression after one line of platinum-based therapy, performance status of 0 to 2, and normal organ function were potentially eligible. Only patients with a ≥ 50% decrease in urinary PGE-M after 5 days of treatment with apricoxib could enroll. Docetaxel 75 mg/m(2) or pemetrexed 500 mg/m(2) once every 21 days per the investigator was administered with apricoxib or placebo 400 mg once per day. The primary end point was progression-free survival (PFS). Exploratory analysis was performed regarding baseline urinary PGE-M and outcomes.In all, 101 patients completed screening, and 72 of the 80 who demonstrated ≥ 50% suppression were randomly assigned to apricoxib or placebo. Toxicity was similar between the arms. No improvement in PFS was seen with apricoxib versus placebo. The median PFS for the control arm was 97 days (95% CI, 52 to 193 days) versus 85 days (95% CI, 67 to 142 days) for the experimental arm (P = .91).Apricoxib did not improve PFS, despite biomarker-driven patient selection.© 2014 by American Society of Clinical Oncology.

Map & Directions

3659 S Miami Ave Ste. 2001 Miami, FL 33133
View Directions In Google Maps

Nearby Doctors

2000 S Dixie Hwy 103
Miami, FL 33133
305 706-6011
3661 S Miami Ave # 505
Miami, FL 33133
305 599-9837
2640 Sw 25Th St
Miami, FL 33133
786 995-5290
3661 S Miami Ave Ste 801
Miami, FL 33133
305 606-6260
1801 Micanopy Ave
Miami, FL 33133
305 624-4127
3659 S Miami Ave Suite 4006
Miami, FL 33133
305 348-8005
3659 S Miami Ave Suite 4006
Miami, FL 33133
305 585-5255
3641 S Miami Ave Suite 331
Miami, FL 33133
305 855-5040
3151 Sw 27Th Ave
Coconut Grove, FL 33133
305 434-4636